

EMA/752307/2017

European Medicines Agency decision

P/0343/2017

of 23 November 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for risankizumab (EMEA-001776-PIP02-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0343/2017

of 23 November 2017

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for risankizumab (EMA-001776-PIP02-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by AbbVie Ltd on 12 April 2017 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 10 November 2017, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for risankizumab, solution for injection, age-appropriate pharmaceutical form, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for risankizumab, solution for injection, age-appropriate pharmaceutical form, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for risankizumab, solution for injection, age-appropriate pharmaceutical form, subcutaneous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to AbbVie Ltd, AbbVie House, Vanwall Road, SL6 4UB - Maidenhead, United Kingdom.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/522018/2017

London, 10 November 2017

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-001776-PIP02-17

Scope of the application

Active substance(s):

Risankizumab

Condition(s):

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis)

Pharmaceutical form(s):

Solution for injection

Age-appropriate pharmaceutical form

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

AbbVie Ltd

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, AbbVie Ltd submitted for agreement to the European Medicines Agency on 12 April 2017 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 24 May 2017.

Supplementary information was provided by the applicant on 8 August 2017. The applicant proposed modifications to the paediatric investigation plan.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
 - to grant a deferral in accordance with Article 21 of said Regulation;
 - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population, Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis)

The waiver applies to:

- the paediatric population from birth to less than 1 year of age;
- solution for injection, age-appropriate pharmaceutical form, subcutaneous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

The waiver applies to:

- the paediatric population from 1 to less than 5 years of age;
- solution for injection, age-appropriate pharmaceutical form, subcutaneous use;
- on the grounds that the specific medicinal product is likely to be ineffective.

2. Paediatric investigation plan

2.1. Condition

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, spondylarthritis and juvenile idiopathic arthritis)

2.1.1. Indication(s) targeted by the PIP

Treatment of juvenile psoriatic arthritis (JIA PsA)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 5 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection, age-appropriate pharmaceutical form

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an age-appropriate pharmaceutical form
Non-clinical studies	0	Not applicable.

Clinical studies	1	Study 2 Double-blind, randomised, placebo controlled withdrawal trial to evaluate safety and efficacy of risankizumab in children and adolescents from 5 to less than 18 years of age with moderate to severe juvenile psoriatic arthritis (JIA-PsA)
Extrapolation, modelling and simulation studies	1	Study 3 Modelling and simulation study to predict risankizumab doses in children and adolescents from 5 to less than 18 years of age with moderate to severe juvenile psoriatic arthritis (JIA-PsA)
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2029
Deferral for one or more measures contained in the paediatric investigation plan:	Yes